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Background: A head-to-head study demonstrated the superiority of once-daily umeclidinium bromide/vilanterol
(UMEC/VI) 62.5/25 mcg on trough forced expiratory volume in 1 s (FEV1) versus once-daily tiotropium/olodaterol
(TIO/OLO) 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease (COPD). This analysis
evaluated the cost effectiveness of UMEC/VI versus TIO/OLO from a Spanish National Healthcare System
perspective, using data from this study and Spanish literature.
Methods: This analysis was conducted from the perspective of the Spanish National Healthcare System with a 3-year
horizon as base case. A disease progression model using a linked risk equation approach was used to estimate
disease progression and associated healthcare costs, and quality-adjusted life years (QALYs). The Evaluation of COPD
Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study was used to develop the statistical risk equations
for clinical endpoints, and costs were calculated using a health state approach (by dyspnea severity). Utilities for QALY
calculation were estimated using patient baseline characteristics within a regression fit to Spanish observational data.
Treatment effect, expressed as change from baseline in FEV1 was obtained from the head-to-head study and used in the
model (UMEC/VI minus TIO/OLO difference: + 52 mL [95% confidence interval: 28, 77]). Baseline patient characteristics
were sourced from Spanish literature or the head-to-head study if unavailable. A scenario analysis using only the
intent-to-treat (ITT) population from the head-to-head study, and sensitivity analyses (including probabilistic
sensitivity analyses), were conducted. Direct healthcare costs (2017 Euro) were obtained from Spanish sources
and costs and benefits were discounted at 3% per annum.
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Results: UMEC/VI was associated with small improvements in QALYs (+ 0.029) over a 3-year time horizon, compared
with TIO/OLO, alongside cost savings of €393/patient. The ITT scenario analysis and sensitivity analyses had similar
results. All probabilistic simulations resulted in UMEC/VI being less costly and more effective than TIO/OLO.
Conclusion: UMEC/VI dominated TIO/OLO (more effective and less expensive). These results may aid payers and
decision-makers in Spain when making judgements on which long-acting muscarinic antagonist/long-acting
β2-agonist (LAMA/LABA) treatments can be considered cost effective in Spain.
Keywords: Bronchodilators, Chronic obstructive pulmonary disease, Cost effectiveness, Economic evaluation, Health
resources, LAMA/LABA, National Healthcare System perspective, QALY, Spain, UtilityBackground
Chronic obstructive pulmonary disease (COPD) is a dis-
abling respiratory disease characterized by airflow limita-
tion and persistent breathing difficulties [1]. COPD is
associated with a high clinical and economic burden
worldwide, impacting the patient’s quality of life and
causing significant costs, associated with clinical care
[1]. In Spain, the prevalence of COPD in patients aged
40–80 years old is approximately 10.2% and prevalence
is higher in men compared with women (15.1% versus
5.6%, respectively) [2]. Geographic variations in preva-
lence range from 6.2–16.9% [3]. The annual cost of
COPD in Spain was estimated at €239 million in 1997
and €507 million in 2000 [4, 5].
Pharmacological treatment for COPD aims to improve
patient symptoms and reduce the risk of exacerbation [1].
The cornerstone of pharmacological therapy for COPD is
bronchodilation with a long-acting muscarinic antagonist
(LAMA), a long-acting β2-agonist (LABA), or a LAMA/
LABA combination either as initial therapy or escalation
from monotherapy, depending on the severity of breath-
lessness and the patient’s risk of exacerbations [1, 6–8].
The Global Initiative for Chronic Obstructive Lung Dis-
ease (GOLD) 2018 report recommends dual LAMA/
LABA therapy for patients initially on monotherapy who
continue to experience exacerbations or patients with se-
vere or persistent breathlessness [1].
The Spanish guidelines for pharmacological treatment
of stable COPD (Guía española de la enfermedad
pulmonar obstructiva crónica, GesEPOC) [9] include
a number of GOLD principles and recommendations;
however, GesEPOC follows an alternative suite of
phenotype-based recommendations for the evaluation
and treatment of COPD [9]. GesEPOC proposes four
phenotypes that determine differential treatment:
non-exacerbators; mixed COPD-asthma; exacerbators
with emphysema; and exacerbators with chronic bron-
chitis [10]. Within this framework, dual LAMA/LABA
therapy is recommended in non-exacerbators who re-
main symptomatic after bronchodilator monotherapy,
and in patients with emphysema or chronic bronchitis
at risk of exacerbations [10].Various LAMA/LABA combinations are currently
available in Spain. Umeclidinium/vilanterol 62.5/25 mcg
(UMEC/VI) is a once-daily single inhaler LAMA/LABA
therapy, approved for the treatment of COPD by the Euro-
pean Medicines Agency (EMA) in 2014 [11]. The safety
and efficacy of UMEC/VI has been extensively investigated
and studies have shown improvements in lung function
with UMEC/VI compared with placebo [12, 13], UMEC or
VI monotherapy [12, 14, 15], tiotropium (TIO) [14, 16, 17]
and inhaled corticosteroid (ICS)/LABA combination ther-
apy [18, 19]. TIO/olodaterol (TIO/OLO) was first approved
as treatment for patients with COPD in 2015 [20]. A recent
systematic literature review demonstrated that treatment
with TIO/OLO provides significant improvement in lung
function when compared with TIO and OLO monothe-
rapies and when compared with ICS/LABA combination
therapy [21].
Until recently, no direct comparison between
once-daily LAMA/LABA combination therapies had
been conducted, although indirect comparisons of
double blind trials highlighted potential for efficacy
differences within the LAMA/LABA treatment class in
favor of UMEC/VI [22, 23]. A 12-week head-to-head
study of UMEC and TIO monotherapies demonstrated
that UMEC was superior to TIO in trough forced
expiratory volume in 1 s (FEV1), with a treatment
difference of 59 mL (95% confidence interval [CI]:29,
88 mL) [24], and a recent open-label, 8-week crossover
head-to-head study demonstrated that this superiority
was maintained when UMEC and TIO were adminis-
tered as part of a LAMA/LABA dual therapy [25].
This LAMA/LABA head-to-head study, UMEC/VI
62.5/25 mcg was compared with TIO/OLO 5/5 mcg
in symptomatic patients with moderate COPD who
were naïve to ICS at study entry [25]. The study
showed that UMEC/VI was superior to TIO/OLO in
the intent-to-treat population for FEV1 improvement
at 8 weeks with a treatment difference of 52 mL (95%
CI: 28, 77 mL) [25].
UMEC/VI has already been shown to be cost effective
when compared with TIO alone from a Spanish National
Healthcare System perspective [26]. Following the
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UMEC/VI and TIO/OLO, this study aimed to assess the
cost effectiveness of UMEC/VI versus TIO/OLO from a
Spanish National Healthcare System perspective [25].
Given that the annual drug acquisition costs for UMEC/
VI are lower than TIO/OLO in Spain, it was anticipated
that this analysis would find that UMEC/VI dominated
TIO/OLO (as a more effective and less expensive treat-
ment). However, testing this hypothesis through sensitiv-
ity analyses is important to demonstrate the robustness
of this assumption and to adequately inform healthcare
decision makers.Methods
Objectives
A cost-effectiveness analysis was performed comparing
once-daily UMEC/VI with once-daily TIO/OLO in symp-
tomatic patients with stable COPD at low risk of exacer-
bations from the perspective of the Spanish National
Healthcare System over a 3-year time horizon, using data
from published literature and the head-to-head study of
UMEC/VI versus TIO/OLO (study funded by GSK, study
number 204990; NCT02799784) [25].Design of the clinical study included in the analysis
The UMEC/VI versus TIO/OLO head-to-head study
was a randomized, 8-week, open-label, two-period cross-
over study in symptomatic patients with moderate
COPD [25]. To minimize the potential for bias in the
assessment of the primary efficacy endpoint of trough
FEV1, given the open-label design, all spirometry assess-
ments were performed by investigational staff blinded to
treatment allocation throughout all study phases. Eligible
patients were ≥ 40 years of age, with a diagnosis of
COPD [27], a modified Medical Research Council
(mMRC) dyspnea score of ≥2, a smoking history ≥10
pack-years, a post-bronchodilator FEV1/forced vital cap-
acity ratio < 0.70 and a post-bronchodilator FEV1 ≤ 70%
and ≥ 50% of predicted normal values.
Patients were randomized to receive UMEC/VI 62.5/
25 mcg one inhalation once daily via the Ellipta dry
powder inhaler for 8 weeks, followed by TIO/OLO
5/5 mcg (via two inhalations once daily of TIO/OLO
2.5/2.5 mcg) using the Respimat soft mist inhaler for
8 weeks, or vice versa, with an interim 3-week washout
between each 8-week treatment period. The primary
endpoint was trough FEV1 at week 8 in both the ITT and
per-protocol (PP) population, with a non-inferiority
margin and superiority margin of − 50 mL and 0 mL for
the lower bound of the 95% CI in the PP and ITT
populations, respectively. Other lung function and
patient-reported outcomes were also assessed [25].Cost-effectiveness model
The GALAXY COPD disease progression model was
used to perform cost-effectiveness calculations; develop-
ment of the model and internal/external validation, have
been previously published [28–32]. A linked risk equa-
tion approach was used within the model to estimate
disease progression. Associated healthcare costs such as
drug costs, hospitalization costs and outpatient visits, as
well as the impact on quality-adjusted life years (QALYs)
and survival were estimated based on the resulting
clinical outcomes. The model assigned general costs of
follow-up based on the proportion of patients with
various levels of dyspnea in each model cycle. Post hoc
analyses of the Evaluation of COPD Longitudinally to
Identify Predictive Surrogate Endpoints (ECLIPSE;
NCT00292552) [33] study was used to develop the
statistical risk equations for the epidemiological framework.
The model uses a 1-year cycle length.
Ethics approval was not required for the study as data
for the model were derived from previously conducted
studies, for which ethical approval had been obtained.
Study perspective
The cost-effectiveness analyses were conducted from a
Spanish National Healthcare System perspective and costs
included direct healthcare-related costs, but not costs
associated with a societal perspective (e.g. non-medical costs
and indirect costs such as absenteeism and presenteeism).
Model inputs
Population
Patient characteristics for the base case analysis were
based on two Spanish observational studies [34, 35], in
order to analyze a population that is representative of
the Spanish population initiating LAMA/LABA therapy.
Where data could not be found, for example for clinical
characteristics, data from the UMEC/VI versus TIO/
OLO head-to-head study were used [25] (Table 1). All
characteristics used for the base case analysis were vali-
dated by three clinical experts from Spain (initials of
clinical experts: MM, BA-N, and FG-R). Data on base-
line fibrinogen concentration and baseline 6-min walk test
(6MWT) distance were not available from the UMEC/VI
versus TIO/OLO head-to-head study; these data were
estimated using equations developed within the model
using baseline data from the ECLIPSE study [33] (Table 1).
Efficacy input parameters
Treatment effect was measured by change from baseline
in post-bronchodilator FEV1, using data from the UMEC/
VI versus TIO/OLO head-to-head study (UMEC/VI:
180 mL; TIO/OLO: 128 mL; difference: 52 mL, 95% CI:
28, 77 mL) [25]. These absolute treatment effects (UMEC/
VI: 180 mL; TIO/OLO: 128 mL) were applied to the
Table 1 Model inputs: baseline demographics by base case and ITT population, and resource costs
Parameters Base case analysis ITT scenario analysis
Female, % 19.2 [34] 39.8
Age (years), mean (SE) 68.2 (0.4) [34] 64.4 (0.6)
Smoking status (current smokers), % 23.1 [35] 53.0
Any cardiovascular comorbidity, % 26.3a 26.3b
Any other comorbidity, % 78.4a 78.4
History of exacerbation, ≥1 moderate or severe in the previous 12 months, % 18.2a 18.2
BMI (kg/m2), %
< 21 7.1 [35] 10
21–30 60.8 [35] 50
> 30 32.1 [35] 40
mMRC score≥ 2, % 100a 100
Number of moderate and severe exacerbations in previous year, mean (SE) 0.2 (0.03)a 0.2 (0.03)
Number of severe exacerbations in previous year as a % of total previous year exacerbations, mean 13.7a 13.7
Baseline FEV1% predicted, mean (SD) 59.6 (5.6)
a 59.6 (5.6)
Baseline FEV1 mL, mean (SE) 1563 (28.6)
a 1563 (28.6)
Height (cm), mean (SE) 167.6 (0.3) [36] 169.9 (0.6)
Fibrinogen (mcg/dL), mean 456.7c 453.2c
SGRQ score, mean (SE) 42.7 (0.3) [56] 43.1 (1.0)d
6MWT distance (m), mean 346.1c 349.9c
Exacerbation event costs (€)
Moderate exacerbation 72.76
Severe exacerbation 4466.09
Annual disease management costs (€/year)
Without dyspnea symptoms 524.87
With dyspnea symptoms several days per week 699.98
With dyspnea symptoms most days per week 925.85
BMI body mass index, FEV1 forced expiratory volume in one second, ITT intent-to-treat; mMRC, modified Medical Research Council, SD standard deviation, SE
standard error; SGRQ St. George’s respiratory questionnaire, 6MWT 6-min walk test
aSpanish data not available from publications so sourced from head-to-head study [25]
bcardiovascular comorbidity defined as any cardiac disorder (coronary artery disease, myocardial infarction, arrhythmia, or congestive heart failure) or
cerebrovascular accident
cpredicted using GALAXY model
dpredicted using GALAXY model SGRQ-C risk equation and converted to SGRQ
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was maintained over the time horizon as long as patients
remained on therapy. The starting FEV1 values and subse-
quent improvements in FEV1 and other COPD disease
factors built into the model at time 0 are outlined in
Additional file 1.Cost inputs
Total costs accounted for the drug acquisition costs, the
costs of exacerbation events (moderate or severe) and
the costs of follow-up according to the frequency of dys-
pnea symptoms. All costs were estimated in 2017 Euros
and were adapted from Spanish sources.National list prices for drug acquisition costs, in-
cluding rescue medications, were sourced from each
cost per pack at price to public plus value added tax
(PTP + VAT), as listed in the 2017 catalogue of sani-
tarian products included in the Spanish National
Healthcare System (Table 2) [37]. The cost per pack
for UMEC/VI and TIO/OLO was €70.25 and €81.49,
respectively. Costs for rescue medications were also
considered within the model; based on the results of
the UMEC/VI versus TIO/OLO head-to-head study
[25], salbutamol 1.77 inhalations per day and 1.51 in-
halations per day were modeled into the TIO/OLO
and UMEC/VI arms, respectively (cost per pack
€2.69; Table 2).
Table 2 Drug acquisition costs
Drug (brand) Drug
(generic)
Dose
(mcg)
Pack size Pack cost (PTP + VAT)a [26]
Pack cost (PTP + VAT)a [26]
Dosing Annual
acquisition costa
Comparator drug costs
Spiolto Respimat TIO/OLO 5/5 30 doses (60
pulsations)
€81.49 2 inhalations once daily €992
Anoro Ellipta UMEC/VI 62.5/
25
30 doses €70.25 1 inhalation once daily €855
Subsequent treatment and other drugs costs
Spiriva
Handihalerb
TIO 18 30 doses €49.06 1 inhalation once daily €597
Seretide
Accuhalerb
SAL/FP 50/
500
60 doses €41.28 1 inhalation twice daily €503
Flixotide
Accuhalerc
FP 500 60 doses €31.47 2 inhalations once daily €383
Ventolind Salbutamol 100 200 doses €2.69 Based on head-to-head study
[25]Based on head-to-head study [25]
aSource: Pack cost is taken from the Ministerio de Sanidad, Servicios Sociales e Igualdad. Available at: https://www.msssi.gob.es/en/home.htm Accessed
February 2018
bTIO + SAL/FP administered together as escalation treatment for both UMEC/VI and TIO/OLO arm in base case
cadded on to UMEC/VI in an escalation strategy tested in a sensitivity analysis
drescue medication, modeled based on data from the head-to-head study [25]: 1.77 dose inhalations per day for TIO/OLO, 1.51 dose inhalations per day
for UMEC/VI
FP fluticasone propionate, PTP price to public, SAL salmeterol xinafoate, TIO/OLO tiotropium/olodaterol, UMEC/VI umeclidinium/vilanterol, VAT value added tax
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the number of exacerbations experienced in each cycle.
Cost for exacerbations and disease management were
sourced from the previous cost-effectiveness analysis in
Spain [26] and were inflated to 2017 Euro valuations using
the Spanish Consumer Price Index [38]. The costs of a
moderate and severe exacerbation were estimated to be
€72.80 and €4470, respectively (Table 1) [26].
Annual disease management costs reflected the level
of follow-up based on the proportion of patients with
various levels of dyspnea in each model cycle (€524.87/
year for a patient without dyspnea symptoms; €699.98/
year for a patient experiencing dyspnea symptoms
several days per week; €925.85/year for patients with
dyspnea symptoms most days per week; Table 1).
Utilities
In this Spanish cost-effectiveness analysis, the model
estimated utilities in the base case analysis via linear
regression for each cycle, using a utility equation developed
for the previous cost-effectiveness analysis of UMEC/VI
versus TIO [26], based on data from an observational study
in Spain [39]. Details of the utility estimates used within this
study, including any modifications made to the Spanish risk
equation from the initial disease progression model [28–32],
are available in Additional file 2.
Model assumptions
Given the disparity between the cycle length (1 year)
and the total duration of the UMEC/VI versus TIO/OLO head-to-head study (8-week treatment periods)
[25], it was assumed that treatment effects started at
0 months, i.e. a delay in treatment effect was not
modeled. Clinically relevant effects have been seen after the
first dose of treatment in favor of UMEC/VI, in studies
performing serial FEV1 assessment [40]. The model also
assumed that treatment effects did not wane over the
duration of the analysis and that the differential treatment
effects observed within the UMEC/VI versus TIO/OLO
head-to-head study were maintained over the time horizon,
as long as patients remained on treatment. This assumption
was validated by the Spanish clinical experts.
Discontinuation rates of 8.7% per year for each arm, were
based on the rates observed in the Understanding Potential
Long-Term Impacts on Function with Tiotropium (UPLIFT;
NCT00144339) trial among GOLD stage 2 patients in the
TIO arm [41]. Once patients discontinued their original
treatment, the analysis assumed patients would escalate to
multiple inhaler triple therapy (ICS, LAMA and LABA in
combination). Spanish clinical experts confirmed the
chosen escalation treatment in Spain as salbutamol/
fluticasone propionate (SAL/FP) 50/500 mcg, two
inhalations per day plus TIO 18 mcg, one inhalation
per day. In the base case, the model assumed that the
lung function of patients who escalated to triple therapy
would not be subject to any lasting benefit from their
initial treatment. Therefore, a + 52 mL benefit in FEV1
was applied for patients escalating from TIO/OLO to
triple therapy (equal to the treatment difference between
UMEC/VI and TIO/OLO) and no change in FEV1 was
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therapy, therefore cancelling the FEV1 benefit conferred
by the initial treatment.
Base case settings
A time horizon of 3 years was employed to align with
the previous UMEC/VI versus TIO cost-effectiveness
analysis [26] and with another cost-effectiveness analysis
performed on treatments for COPD [42]. Costs and ben-
efits were discounted at 3% per year in line with Spanish
guidelines for economic evaluation [43].
Model outputs
The model estimated: exacerbation rates (number of mod-
erate and severe exacerbations per patient per year), costs
(total, drug, non-drug; discounted), survival, life-years
(LY) gained (undiscounted), QALYs gained (discounted),
and incremental cost effectiveness per LY and per QALY
gained (i.e. the cost effectiveness of each treatment for
each year of survival [LY] and for each LY adjusted for
quality of life [QALY]).
Sensitivity and scenario analyses
A scenario analysis was conducted using baseline char-
acteristics from the ITT population from the UMEC/VITable 3 Deterministic sensitivity analyses
Parameter Base case
Time horizon 3 years
Discount rate 3%
Patient population and utility
estimation
Equation developed in the previous
cost-effectiveness analysis [26], base
on an observational Spanish study [
FEV1 treatment effect UMEC/VI 180 mL, TIO/OLO 128 mL
(incremental FEV1 treatment effect
of 52 mL (favoring UMEC/VI)
Treatment discontinuation 8.7%
Subsequent treatment SAL/FP 50/500 mcg, two inhalations
per day + TIO 18 mcg
Costing for dyspneab €524.87/year; €699.98/year;
€925.85/year
Costing for exacerbationsb Moderate €72.76c; severe €4466.09d
CI confidence interval, ED emergency department, FEV1 forced expiratory volume in
corticosteroid, SAL salmeterol xinafoate, TIO/OLO tiotropium/olodaterol, UMEC/VI um
Function with Tiotropium
aThis sensitivity analysis assumed that patients in both the UMEC/VI and TIO/OLO a
(assumed to be + 52 mL)
binflated to 2017 Euros using the Consumer Price Index [38]
ccost of OCS and/or antibiotics, one primary care visit and one ED visit for 4.3% pat
dcost of one primary care visit, one ED visit, and hospitalization for 8 daysversus TIO/OLO head-to-head study (Table 1) [25]. All
other parameters remained as per the base case, with
the exception of utilities, which are outlined below.
In the ITT scenario analysis, utilities were estimated
using the GALAXY model algorithm [28, 29], based on St.
George’s Respiratory Questionnaire for COPD patients
(SGRQ-C) in each model cycle. First, the pooled baseline
COPD Assessment Test (CAT) in the UMEC/VI versus
TIO/OLO study (mean: 17.76, standard error [SE]: 0.46)
was re-scaled to match the 0–100 range of SGRQ-C, by
multiplying by 2.5 (estimated SGRQ-C: 44.4). Second,
SGRQ-C was converted to SGRQ using the following
conversion: SGRQ= [SGRQ-C*0.9] + 3.1 = 43.1. At baseline,
this provided an estimate for SGRQ value of 43.1.
This baseline SGRQ value was transformed into an
EuroQol-5 Dimension questionnaire (EQ-5D) utility
estimate using the algorithm developed by Starkie et al. [44]:
EQ-5D = 0.9617–0.0013*SGRQ total − 0.0001*SGRQ total2
+ 0.0231*%male. The corresponding baseline EQ-5D utility
score was 0.743. Utilities in subsequent cycles were calcu-
lated from the SGRQ-C scores using the same approach.
Deterministic sensitivity analyses were conducted
to examine the impact of changing certain model
parameters estimates and are listed in Table 3. A
threshold analysis was also conducted on the priceSensitivity analysis
1,5 and 10 years and lifetime (25 years) time horizons
0% and 5%
d
39]
Base case population with utilities estimated from GALAXY
utility algorithm
ITT study population with utilities estimated from GALAXY
utility algorithm
ITT study population with utilities estimated from GALAXY
utility algorithm over a lifetime horizon
Equal FEV1 treatment effect (128 mL) for UMEC/VI and
TIO/OLO
Incremental FEV1 treatment effect with UMEC/VI equal
to the upper (+ 77 mL) and lower (+ 28 mL) 95% CI
50% for year 1 (from population-based, retrospective,
observational study in Catalonia [55]) and 8.7%
(from the UPLIFT trial [41]) for subsequent years
Patients on UMEC/VI add FP 500 mcg, two inhalations
per day; patients on TIO/OLO escalate to SAL/FP
500/50 mcg, two inhalations per day + TIO 18 mcg,
one inhalation per daya
Cost of level of dyspnea ±20%
Cost of exacerbations ±20%
one second, FP fluticasone propionate, ITT intent-to-treat, OCS oral
eclidinium vilanterol, UPLIFT Understanding Potential Long-Term Impacts on
rms experienced the same FEV1 improvement upon escalating to triple therapy
ients
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€30,000/QALY.
Probabilistic sensitivity analysis
Probabilistic sensitivity analyses (PSA) were conducted
to address the uncertainty in the model input values, by
assigning distributions to input parameters and
randomly sampling from these distributions over 2000
simulations. Two probabilistic analyses were conducted:
one for the base case and one for the ITT scenario
analysis. Discontinuation rates used beta distributions
with SE equal to 20% of the point estimates. Treatment
effects on FEV1 was assigned a normal distribution with
the observed 95% CIs. Exacerbation event costs and
annual health state costs used a gamma distribution with
SE equal to 20% of the point estimate. Risk equation
coefficients were sampled using correlated draws from a
Cholesky decomposition table, obtained from the covariance
matrices for each equation [28].
Results
In the base case analysis, UMEC/VI was associated with
fewer exacerbations (− 0.014 per year) and improvements
in survival (+ 0.004 LYs) and quality of life (+ 0.029
QALYs) over a 3-year time horizon, when compared with
TIO/OLO. Treatment with UMEC/VI also resulted in a
cost saving of €393 per patient (Table 4).Table 4 Model results: base case
Deterministic TIO/OLO UMEC/VI Difference
Average number of exacerbations, per patient per life-year
Severe 0.074 0.070 −0.004
Total (moderate and severe) 0.589 0.575 −0.014
Outcomes at end of 3 years
Survival at end of time horizon 89.9% 90.3% 0.4%
Undiscounted Lys 2.870 2.874 0.004
Discounted (3% p.a.) QALY 2.118 2.147 0.029
Costs at end of 3 years
Drug costs €2820 €2490 −€335
Non-drug costs €3210 €3160 −€58
Exacerbation event costs €1020 €973 −€47
Health state costs
(by dyspnea severity)
€2190 €2180 −€10
Total costs €6040 €5640 −€393
Incremental results (versus TIO/OLO)
ICER (€ per QALY gained) Dominant
ICER (€ per LY gained) Dominant
Cost and cost-effectiveness data are presented to three significant figures for
values of four figures or more, and to the nearest Euro for values of three
figures or less
ICER incremental cost-effectiveness ratio, LY life years, QALY quality-adjusted
life-year, p.a. per annum, TIO/OLO tiotropium/olodaterol,
UMEC/VI umeclidinium/vilanterolThe results of the ITT scenario analysis were consist-
ent with the base case, showing that UMEC/VI was as-
sociated with fewer exacerbations (− 0.014 per year) and
improvements in survival (+ 0.003 LYs) and quality of
life (+ 0.009 QALY) over a 3-year time horizon, when
compared with TIO/OLO, alongside cost savings of
€396 per patient (Table 5).
The results of sensitivity analyses are presented in
Table 6, looking at the impact of the time horizon, dis-
count rates, patient population and utility estimation,
treatment effect, discontinuation, subsequent treatment,
and costings on the model outcomes. UMEC/VI was
found to be dominant (better outcomes and reduced
costs) compared with TIO/OLO in all analyses, with the
exception of one analysis (equal FEV1 absolute treatment
effect in both arms [128 mL]), whereby UMEC/VI was
considered equally effective but less expensive (Table 6).
A sensitivity analysis conducted on the price of TIO/
OLO found that UMEC/VI was cost effective at a
willingness-to-pay threshold of €30,000/QALY until the
price of TIO/OLO fell to €39.66 (51% reduction from its
current list price at €81.49).
The probabilistic sensitivity analyses showed UMEC/
VI to be more effective and less expensive than TIO/
OLO in 100% of the simulations in the cost-effectiveness
scatter plot, in both the base case and ITT scenario ana-
lysis (Fig. 1). In the base case PSA, mean costs (95% CI)
for UMEC/VI and TIO/OLO were €5660 (€5000, €6410)
and €6060 (€5380, €6830), respectively. Mean QALYs
(95% CI) were 2.15 (2.08, 2.21) and 2.12 (2.05, 2.18) for
UMEC/VI and TIO/OLO, respectively. In the ITT scenario
PSA, mean costs (95% CI) for UMEC/VI and TIO/OLO
were €5740 (€5060, €6490) and €6140 (€5460, €6910),
respectively. Mean QALYs (95% CI) were 2.06 (1.98, 2.13)
and 2.05 (1.97, 2.12) for UMEC/VI and TIO/OLO,
respectively.
Discussion
This study aimed to assess the cost effectiveness of
UMEC/VI versus TIO/OLO from a Spanish National
Healthcare System perspective. The results of this
analysis with a Spanish population as base case, demon-
strated that UMEC/VI dominated TIO/OLO, providing
gains in LYs and QALYs (+ 0.004 and + 0.029, respect-
ively) alongside total cost savings of €393 per patient
over 3 years. Drug costs were the main driver of the
total costs savings, followed by non-drug costs, specific-
ally costs associated with exacerbation events. The
model also showed small numerical reductions in total
exacerbation rates (− 0.014 exacerbations per year) with
UMEC/VI compared with TIO/OLO. The results within
the ITT scenario analysis using the UMEC/VI versus
TIO/OLO head-to-head study population were consist-
ent with the base case, with UMEC/VI shown to be
Table 5 Model results: ITT scenario analysis
Deterministic TIO/OLO UMEC/VI Difference
Average number of exacerbations, per patient per life-year
Severe 0.077 0.074 −0.004
Total 0.613 0.599 −0.014
Outcomes at end of 3 years
Survival at end of time horizon 91.1% 91.4% 0.3%
Undiscounted LYs 2.885 2.889 0.003
Discounted (3% p.a.) QALYs 2.050 2.060 0.009
Costs at end of 3 years
Drug costs €2840 €2500 −€337
Non-drug costs €3300 €3240 −€58
Exacerbation event costs €1080 €1030 −€48
Health state costs (by dyspnea) €2220 €2210 −€10
Total costs €6130 €5740 −€396
Incremental results (versus TIO/OLO)
ICER (€ per QALY gained) Dominant
ICER (€ per LY gained) Dominant
Cost and cost-effectiveness data are presented to three significant figures for
values of four figures or more, and to the nearest Euro for values of three
figures or less
ICER incremental cost-effectiveness ratio, ITT intention-to-treat, LY life years,
p.a. per annum, QALY quality-adjusted life-year, TIO/OLO tiotropium/olodaterol,
UMEC/VI umeclidinium/vilanterol
Driessen et al. Respiratory Research          (2018) 19:224 Page 8 of 13more effective than TIO/OLO and at a lower cost. The
dominance of UMEC/VI over TIO/OLO demonstrated
in both the base case and the ITT scenario analyses were
maintained when a 5- and 10-year time horizon was
employed, and across several sensitivity analyses. The
results of the ITT utility estimation scenario analysis are
particularly relevant when considering the cost effective-
ness of UMEC/VI versus TIO/OLO outside of the
Spanish National Healthcare System perspective. Two
sensitivity analyses were conducted using the ITT
population from the UMEC/VI versus TIO/OLO
head-to-head study [25], with a utility estimation based
on the GALAXY utility algorithm [28, 29], which
converted SGRQ scores to utilities according to the
algorithm of Starkie et al. [44]. Both analyses, one of
which was over a 3-year period and one of which used a
lifetime time horizon, demonstrated that UMEC/VI
dominated TIO/OLO as the more effective and less ex-
pensive treatment. While these sensitivity analyses used
Spanish costs, they would nevertheless provide the most
applicable platform by which to estimate the cost effec-
tiveness of UMEC/VI versus TIO/OLO from other na-
tional perspectives, using nationally derived cost inputs.
Although UMEC/VI was statistically superior to TIO/
OLO in terms of trough FEV1 improvement [25], a
sensitivity analysis considered the possibility of equal FEV1
benefit for both treatments; in this scenario, UMEC/VI was
a cost-saving treatment option compared with TIO/OLO(as UMEC/VI has a lower acquisition cost). The sensitivity
analyses also demonstrated that UMEC/VI QALY gains
increased with the time horizon, from 0.029 QALYs in the
3-year time horizon used for the base case analysis to 0.091
QALYs in the lifetime horizon. These are relatively low
QALY gains, however it should be noted that 95% of the
population used within the base case had a low exacerbation
risk (GOLD stage B) and high symptom burden (100% of
patients had an mMRC score ≥ 2) and only 5% were
classified as having a high exacerbation risk (GOLD
stage D) [25]. Given the sensitivity of the model to
exacerbations, this may account for the relatively low
QALY gains observed.
Given that UMEC/VI has demonstrated improved effi-
cacy when compared with TIO/OLO [25], and that
UMEC/VI is less expensive than TIO/OLO in Spain, it
was anticipated that this analysis would find that
UMEC/VI dominated TIO/OLO as a more effective and
less expensive treatment. Nevertheless, it was considered
important to challenge this hypothesis using both a
Spanish population as base case, and a more generalized
population within a scenario analysis, in order to dem-
onstrate the robustness of the data supporting the cost
effectiveness of UMEC/VI versus TIO/OLO. While this
cost effectiveness was performed from a Spanish
National Healthcare System perspective, its results are
generalizable to other countries, as indicated by the ITT
scenario analysis, especially in relation to the health
gains observed (costs are more likely to vary according
to each country).
In the base case results, patients gained more QALYs
than LYs, indicating that the treatment effect of UMEC/
VI on FEV1 benefit was associated with improvement in
quality of life, but little to no reduction in mortality,
which is likely the result of modeling treatment effect
based on FEV1 benefit. These results are consistent with
previous studies of UMEC/VI and with systematic re-
views and meta-analyses of other therapies, which have
found that FEV1 benefit is associated with improvement
in quality of life, but little to no reduction in mortality
[12, 16, 45, 46]. A similar result was observed within the
ITT scenario analysis; however, the magnitude of benefit
was lower in this population compared with the base
case, possibly due to the different approaches to utility
estimation used within the base case and ITT analyses.
The Spanish utility equation used within the base case,
and the SGRQ-C equation used within the ITT analysis
considered different variables and would therefore be
sensitive to different parameters. In addition, the popula-
tions used within each equation would lead to different
estimates of utility.
This study is the first to compare two LAMA/LABA
dual therapies using direct head-to-head data from a
randomized, 12-week study [24], which is the most
Table 6 Model results: sensitivity analyses
Sensitivity analyses Incremental
costs
Incremental
QALY
ICER
(€ per QALY gained)
Base case −€393 0.029 Dominant
Time horizon
1 year −€152 0.010 Dominant
5 years −€562 0.043 Dominant
10 years −€752 0.071 Dominant
Lifetime (25 years) −€774 0.091 Dominant
Discount rate for costs and benefits
0% −€405 0.029 Dominant
5% −€388 0.027 Dominant
Patient population and utility estimation
Base case population with utilities estimated from the GALAXY utility algorithm −€393 0.010 Dominant
Use ITT study population with utilities estimated from the GALAXY utility algorithm −€396 0.009 Dominant
Use ITT study population with utilities estimated from the GALAXY utility algorithm
with life time horizon
−€781 0.052 Dominant
Treatment effect
Analysis with equal FEV1 treatment effect (128 mL) across UMEC/VI and TIO/OLO
arms after initiating therapy
−€338 0.000 Equally effective, less expensive
Incremental FEV1 treatment effect with UMEC/VI after initiating therapy equal to
the upper 95% CI (+ 77 mL)
−€420 0.041 Dominant
Incremental FEV1 treatment effect with UMEC/VI after initiating therapy equal to
the lower 95% CI (+ 28 mL)
−€362 0.012 Dominant
Treatment discontinuation
Treatment discontinuation rates from first year sourced from population-based,
retrospective, observational study in Catalonia (50%) and from the UPLIFT trial
for subsequent years (8.7%)
−€252 0.018 Dominant
Subsequent treatment
Patients on UMEC/VI escalate to UMEC/VI and FP 500 mcg, two inhalations
per day while patients on TIO/OLO escalate to SAL/FP 500/50 mcg, two
inhalations per day + TIO 18 mcg, one inhalation per day
−€355 0.032 Dominant
Costing
Cost of level of dyspnea plus 20% −€397 0.029 Dominant
Cost of level of dyspnea minus 20% −€392 0.029 Dominant
Cost of exacerbations plus 20% −€404 0.029 Dominant
Cost of exacerbations minus 20% −€385 0.029 Dominant
CI confidence interval, FEV1 forced expiratory volume in one second, FP fluticasone propionate, ICER incremental cost-effectiveness ratio, ITT intention-to-treat,
LY life years, QALY quality-adjusted life-year; SAL salmeterol xinafoate, TIO/OLO tiotropium/olodaterol, UMEC/VI umeclidinium/vilanterol, UPLIFT Understanding
Potential Long-Term Impacts on Function with Tiotropium
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model [24]. Other studies have compared LAMA/LABA
dual therapy using models with assumptions based on
network meta-analyses [47, 48], or have used head-to
-head data to compare UMEC/VI with TIO monotherapy
[26, 49]. For example, a UK cost-effectiveness analysis of
TIO/OLO found that costs and QALYs associated with
TIO/OLO were equal to those of UMEC/VI and IND/
GLY. However, this study was based on indirect data from
a network meta-analysis and assumed equal efficacy and
equal acquisition costs for LAMA/LABA comparators[48]. Similarly, a cost-effectiveness analysis conducted in
Spain used efficacy inputs derived from a meta-analysis
and found that aclidinium/formoterol (ACL/FF) 400/12
mcg provided the same health benefits as TIO/OLO in
terms of LYs (4.073) and QALYs (2.928), but that ACL/FF
was associated with lower costs (−€332) over a 5-year time
horizon [47]. An additional cost-effectiveness analysis
conducted in the US found UMEC/VI to be equally effec-
tive but less costly compared with open dual LAMA/
LABA combination, with efficacy inputs derived from two
clinical studies [14, 16, 49].
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-600
-500
-400
-300
-200
-100
0
0
100
-600
-500
-400
-300
-200
-100
100
-0.01 0.01 0.02 0.03 0.04 0.05 0.06
-0.01 0.01 0.02 0.03 0.04 0.05 0.06
Probabilistic result Deterministic result
a
b
In
cr
em
en
ta
l c
os
ts
 (
€
)
Incremental QALYs
Incremental QALYs
In
cr
em
en
ta
l c
os
ts
 (
€
)
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from a Spanish National Healthcare System perspective,
using direct head-to-head data. One study compared UMEC
and TIO [50], using direct head-to-head data from a
12-week study whereby in which UMEC was found to be su-
perior to TIO for trough FEV1 in the ITT population (treat-
ment difference: 53 mL, 95% CI: 25, 81 mL; p < 0.001) [24].
Results from this cost-effectiveness analysis using direct
head-to-head data from the UMEC and TIO study showed
results comparable to our study, whereby UMEC dominated
TIO, gaining similar 0.014 QALYs and demonstrating cost
savings of €192 [50]. Another Spanish cost-effectiveness ana-
lysis of UMEC/VI versus TIO alone estimated 3-year costs
of €6215 and QALYs of 2.025 for patients treated with
UMEC/VI and found UMEC/VI to be more effective and
costlier than TIO monotherapy, with an incremental
cost-effectiveness ratio (ICER) of €21,475/QALY [26]. The
higher QALYs and lower costs for UMEC/VI in our base
case analysis reflect the patient population characteristics at
baseline. The Spanish population in our analysis had fewer
current smokers, was less obese, had a lower cardiovascular
disease comorbidity, experienced fewer exacerbations and
had a higher FEV1% predicted at baseline compared with
the population in the Spanish cost-effectiveness analysis of
UMEC/VI versus TIO [26].
The cost effectiveness analysis presented here could be
a conservative estimate, as some medical costs such as
costs associated with inhaler misuse, were not taken into
account within the model [51, 52]. Poor inhalationtechnique can lead to poor disease control and the costs
associated with critical errors are considerable [51, 52].
In Spain, total costs associated with poor inhalation
technique were estimated at €155 million in 2015, repre-
senting 15.5% of the total costs associated with unsche-
duled healthcare visits [51]. A recent study compared
the Ellipta device with other commonly used inhaler
devices, and the results demonstrated that fewer patients
had at least one critical error using the Ellipta device
compared with five alternative inhalers [53]. In addition,
the Ellipta inhaler received more positive patient feed-
back in terms of ease of use in the UMEC/VI versus
TIO/OLO head-to-head study, compared with the
Respimat inhaler [25]. Inhaler training was provided in
the UMEC/VI versus TIO/OLO head-to-head study, and
inhaler technique was routinely checked, thus reiterating
how the results of this cost-effectiveness analysis are
likely to be a conservative estimate of treatment diffe-
rence, as they do not fully reflect the development of
poor technique over time and variation in inhaler train-
ing seen in a real-world setting.
The results of this study are based on data from the
8-week UMEC/VI versus TIO/OLO head-to-head study
[25]. Future studies to confirm the results observed
within this direct treatment comparison, and to compare
the cost effectiveness of LAMA/LABA dual therapies
over a longer duration, would be beneficial in further
helping payers make informed judgements on the cost
effectiveness of LAMA/LABA therapies.
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data on the use of LAMA/LABA combination therapy
for a longer duration than the timeframes considered
within this analysis (3 years, 5 years, 10 years and life-
time), certain assumptions were made within this model.
One such assumption was that treatment effects began
at the outset of the analysis (month 0) in both arms.
This assumption is supported by data from studies that
demonstrated observable, significant improvement in
FEV1 from the first dose [12, 40]. The model also
assumed that treatment effect remained constant for the
duration of the study, as long as patients remained on
treatment. Treatment effect differences between UMEC/
VI and TIO/OLO may be driven by the differences seen
between the LAMA components UMEC and TIO.
A randomized, blinded, 12-week parallel group study
demonstrated superiority of UMEC over TIO on the pri-
mary endpoint of trough FEV1 [24], and the Understand-
ing Potential Long-Term Impacts on Function with
Tiotropium (UPLIFT) study showed that LAMA treat-
ment effects on FEV1 and health status do not wane over
time (at least up to 4 years) [54]. This was shown in both
the overall population [54] and the subgroup of patients
with GOLD stage II COPD [41], as included in the
analysis presented here. An additional study demonstrated
significant improvement in FEV1 for patients treated with
UMEC/VI, and this treatment benefit was maintained
over 6 months [12]. Based on these previous studies, it
was therefore reasonable to assume that the differential
treatment effect seen between UMEC/VI and TIO/OLO
would be maintained over a 3-year time period [24, 54].
Discontinuation rates used within the base case were
based on data from the UPLIFT study [41], as it provides
data over a 4-year follow-up, and this approach was vali-
dated by Spanish clinical experts [41]. Nevertheless, a sen-
sitivity analysis was conducted using 50% discontinuation
rates sourced from an observational study in Catalonia
[55], and UMEC/VI remained dominant compared with
TIO/OLO. Data on escalation to triple therapy from
LAMA/LABA therapy are also not available from pre-
vious clinical studies, therefore it was necessary to make
an assumption regarding the changes in FEV1 once a
patient escalated to subsequent triple therapy (LAMA/
LABA+ICS). The base case assumed that patients would
escalate to the same triple therapy regimen, and that FEV1
treatment effect once on triple therapy would be the same
between arms. This may have been a conservative assump-
tion as it assumed that patients treated with UMEC/VI did
not experience a change in FEV1 after they initiated ICS
therapy. Indeed, this assumption was tested in a sensitivity
analysis and an increase in QALY gains of 0.004 versus the
base case was observed. Finally, data on baseline fibrinogen
concentration and 6MWT distances were not available
from the sources used for this analysis and had to beestimated within the model. It may be informative to collect
and include such data within future studies to assist further
cost-effectiveness evaluations.
Conclusions
This analysis has shown UMEC/VI to be both more
effective and less expensive than TIO/OLO for patients
with symptomatic COPD in Spain, providing small
additional gains in LY (0.004) and QALY (0.029), as well
as a cost saving of €393 per patient over a 3-year time
period. Scenario and sensitivity analyses demonstrated
results consistent with the base case. These data may aid
payers in making judgements on which LAMA/LABA
treatments can be considered cost effective in a Spanish
setting.
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